NCT06252805Not yet recruiting
Severe Prospective Observational COPD Catalonia
Severe Prospective Observational Study of COPD in Catalonia
Source: ClinicalTrials.gov · Last updated 12 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Multicenter observational study to characterize and follow-up a cohort of patients with severe chronic obstructive pulmonary disease (COPD) in Catalonia
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 450 (estimated)
- First submitted
- 2 Oct 2023
- Start date
- 10 Mar 2024
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- Ferran Morell
- Diseases
- COPD
- NCT number
- NCT06252805
What you commit to
- Study type: Observational
- Planned participants: 450
- From 10 Mar 2024 to the primary completion date, 31 Mar 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects affected mainly by another severe chronic respiratory disease that justifies the ventilatory alteration, for example pulmonary fibrosis or severe bronchiectasis
Other
- Subjects not giving written informed consent.
- Subjects at risk of non-compliance, or unable to comply with the scheduled visits.
- Subjects with carcinoma that has not been in complete remission for at least 5 years.
- Subjects with α1-antitrypsin deficiency as the underlying cause of COPD
Who the study is looking for
- Informed consent: a signed and dated written informed consent prior to study participation
- Age: Subjects 35 years of age or order at visit 1.
- Severe COPD diagnosis: an established severe COPD defined by spirometry values:
- A post-albuterol/salbutamol FEV1/FVC ratio of \<0.70 at visit 1. FEV1: forced expiratory volume at one second FVC: forced vital capacity.
- A post-bronchodilator FEV1 \< 50% predicted normal
- Smoking history: ≥ 10 pack-years at visit 1
- Stable phase of the disease (not less than 4 weeks of stability prior visit 1)
Age in the registry: 35 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.